Literature DB >> 16286744

Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis.

Christian Tran1, Jann Lübbe, Olivier Sorg, Laurence Doelker, Pierre Carraux, Christophe Antille, Denise Grand, Evelyne Leemans, Gürkan Kaya, Jean-Hilaire Saurat.   

Abstract

BACKGROUND: An increased incidence of ultraviolet-light-related skin tumours is a well-known problem in patients undergoing posttransplantation immunosuppression with systemic calcineurin inhibitors such as cyclosporine A or tacrolimus. UV-related carcinogenesis as a consequence of long-term treatment of sun-exposed sites with topical calcineurin inhibitors is therefore of theoretical concern.
RESULTS: In this study, we show that tacrolimus acts as a UVB filter when incorporated into liposome membranes. In hairless mice pretreated with 1% pimecrolimus cream, 0.1% tacrolimus ointment or vehicle, the amount of epidermal thymine dimers, measured 1 h after 1 J/cm2 of UVB irradiation, was decreased by 89, 84 and 47%, respectively, as compared to untreated mice. Forty-eight hours after UVB irradiation, 97, 89 and 93% of epidermal thymine dimer levels were removed in pimecrolimus-, tacrolimus- or vehicle-treated mice, respectively. In contrast, 69% of thymine dimers, originally present in much higher amounts than in treated mice, were removed from untreated controls. UVB-induced apoptosis was less pronounced in treated mice.
CONCLUSION: Taken together, these results suggest that topical calcineurin inhibitors prevent DNA photodamage due to a filter effect of both vehicle and active components, whereas they do not affect the clearance of DNA photoproducts. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286744     DOI: 10.1159/000088505

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  The unintended effects of a boxed warning.

Authors:  Roger Ceilley; Andrew Eisenthal
Journal:  J Clin Aesthet Dermatol       Date:  2009-09

Review 2.  Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.

Authors:  Jonathan M Spergel; Donald Y M Leung
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 3.  Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.

Authors:  Seth J Orlow
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 4.  The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Authors:  Johannes Ring; Matthias Möhrenschlager; Verena Henkel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 5.  A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.

Authors:  Mark Lebwohl; Tara Gower
Journal:  MedGenMed       Date:  2006-10-10

Review 6.  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs.

Authors:  Catharina M Lerche; Hans Christian Wulf
Journal:  Dermatol Reports       Date:  2010-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.